GNLX vs. IOBT, ASRT, CUE, BYSI, ADAG, ALLK, CTXR, ORMP, CLSD, and ETON
Should you be buying Genelux stock or one of its competitors? The main competitors of Genelux include IO Biotech (IOBT), Assertio (ASRT), Cue Biopharma (CUE), BeyondSpring (BYSI), Adagene (ADAG), Allakos (ALLK), Citius Pharmaceuticals (CTXR), Oramed Pharmaceuticals (ORMP), Clearside Biomedical (CLSD), and Eton Pharmaceuticals (ETON). These companies are all part of the "pharmaceutical preparations" industry.
Genelux (NASDAQ:GNLX) and IO Biotech (NASDAQ:IOBT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, community ranking, profitability, media sentiment, earnings, risk and valuation.
Genelux has a beta of -1.18, indicating that its share price is 218% less volatile than the S&P 500. Comparatively, IO Biotech has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500.
In the previous week, IO Biotech had 7 more articles in the media than Genelux. MarketBeat recorded 16 mentions for IO Biotech and 9 mentions for Genelux. IO Biotech's average media sentiment score of 0.99 beat Genelux's score of -0.19 indicating that IO Biotech is being referred to more favorably in the news media.
IO Biotech received 6 more outperform votes than Genelux when rated by MarketBeat users. However, 100.00% of users gave Genelux an outperform vote while only 87.50% of users gave IO Biotech an outperform vote.
Genelux has higher revenue and earnings than IO Biotech. Genelux is trading at a lower price-to-earnings ratio than IO Biotech, indicating that it is currently the more affordable of the two stocks.
Genelux presently has a consensus price target of $34.00, suggesting a potential upside of 831.51%. IO Biotech has a consensus price target of $9.67, suggesting a potential upside of 600.48%. Given Genelux's higher probable upside, research analysts plainly believe Genelux is more favorable than IO Biotech.
37.3% of Genelux shares are held by institutional investors. Comparatively, 54.8% of IO Biotech shares are held by institutional investors. 11.7% of Genelux shares are held by company insiders. Comparatively, 2.3% of IO Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
IO Biotech's return on equity of -69.31% beat Genelux's return on equity.
Summary
IO Biotech beats Genelux on 8 of the 15 factors compared between the two stocks.
Get Genelux News Delivered to You Automatically
Sign up to receive the latest news and ratings for GNLX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GNLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
